BerandaEKSO • NASDAQ
add
Ekso Bionics Holdings Inc
Tutup sebelumnya
$0,64
Rentang hari
$0,61 - $0,67
Rentang tahun
$0,50 - $2,35
Kapitalisasi pasar
13,88 jt USD
Volume Rata-Rata
2,03 jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 4,13 jt | -10,38% |
Biaya operasional | 4,85 jt | -10,01% |
Laba bersih | -2,07 jt | 38,42% |
Margin laba bersih | -50,18 | 31,30% |
Penghasilan per saham | — | — |
EBITDA | -2,23 jt | 10,97% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 8,29 jt | -16,55% |
Total aset | 29,21 jt | -6,33% |
Total liabilitas | 14,34 jt | -9,96% |
Total ekuitas | 14,87 jt | — |
Saham yang beredar | 22,00 jt | — |
Harga terhadap nilai buku | 0,95 | — |
Tingkat pengembalian aset | -23,48% | — |
Tingkat pengembalian modal | -33,02% | — |
Arus Kas
Perubahan kas bersih
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -2,07 jt | 38,42% |
Kas dari operasi | -2,28 jt | 32,09% |
Kas dari investasi | -8,00 rb | 52,94% |
Kas dari pembiayaan | 4,69 jt | — |
Perubahan kas bersih | 2,41 jt | 171,42% |
Arus kas bebas | -1,11 jt | 57,80% |
Tentang
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
CEO
Didirikan
2005
Kantor pusat
Situs
Karyawan
70